Toro Company vice president Amy Dahl to depart at end of September
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $65.00 price target on Structure Therapeutics (NASDAQ:GPCR) stock on Wednesday. The target represents significant upside potential from the current price of $21.79, with analyst targets ranging from $37 to $120. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.
The research firm noted direct similarities between orforglipron and Structure Therapeutics’ aleniglipron (aleni) due to comparable scaffold and chemical structure, suggesting potential performance parallels.
Cantor Fitzgerald estimates that orforglipron achieved approximately 11% placebo-adjusted weight loss at 36 weeks, slightly exceeding their initial projections due to differences in the weight loss curve.
Structure Therapeutics has previously indicated that tolerability benchmarks for aleniglipron’s Phase 2B trials should be measured against orforglipron’s Phase 2B obesity trial results.
The company recently announced that its data monitoring committee has approved dosing up to higher 240 mg levels in ongoing Phase 2B trials, which Cantor Fitzgerald interprets as an absence of liver toxicity concerns even at doses with higher exposure.
In other recent news, Structure Therapeutics has been the subject of several analyst updates and ratings. JMP Securities reiterated its Market Outperform rating with a price target of $87.00, emphasizing positive safety data from Eli Lilly’s orforglipron, which is seen as beneficial for Structure Therapeutics’ aleniglipron. Cantor Fitzgerald also maintained an Overweight rating with a $65.00 price target, pointing to significant upcoming Phase 2B obesity trial results expected by the end of 2025. Meanwhile, Guggenheim adjusted its price target slightly lower to $90.00 from $92.00 but kept a Buy rating, noting that the company reaffirmed its timeline for important trial data release.
JMP Securities also adjusted its price target to $87.00 from $89.00, still maintaining a Market Outperform rating, with expectations of potential stock movement linked to upcoming Eli Lilly data. Additionally, Clear Street initiated coverage with a Buy rating and a $61.00 price target, highlighting Structure Therapeutics as a promising player in the oral drug market. These developments reflect ongoing interest and varied perspectives from analysts regarding Structure Therapeutics’ future performance and potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.